Literature DB >> 16278522

Changes in the continuation of antihypertensive drug use after ALLHAT.

Fagen Xie1, Diana B Petitti, Joel Handler.   

Abstract

An analysis was performed of the 1-year continued use of various antihypertensive agents in a health maintenance organization following the 2002 publication of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Computer-stored information was used from the health maintenance organization's prescription information system. Only patients newly started on antihypertensive medications in 2001 and the calendar year following the ALLHAT publication were analyzed. Patients were considered to be persistent with their first prescribed antihypertensive drug class if they obtained at least one refill for the same class of antihypertensive agents on or within 3 months of the end of the 1-year follow-up period. The overall 1-year continuation rate decreased from 2001 to 2003. However, the continuation of thiazide-type diuretic use after ALLHAT (2003) was higher than that before ALLHAT (2001) (p=0.004), whereas the continuation rate was lower for all other drug classes. We provide data to suggest that evidence from randomized trials is one factor influencing the continued use of antihypertensive medication.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16278522      PMCID: PMC8109403          DOI: 10.1111/j.1524-6175.2005.04788.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  18 in total

Review 1.  Compliance, quality of life, and cost effectiveness.

Authors:  W B Stason
Journal:  Curr Hypertens Rep       Date:  1999-12       Impact factor: 5.369

2.  Changes in prescribing patterns following publication of the ALLHAT trial.

Authors:  Peter C Austin; Muhammad M Mamdani; Karen Tu; Merrick Zwarenstein
Journal:  JAMA       Date:  2004-01-07       Impact factor: 56.272

3.  Prescribing patterns for antihypertensive drugs after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: report of experience in a health maintenance organization.

Authors:  Fagen Xie; Diana B Petitti; Wansu Chen
Journal:  Am J Hypertens       Date:  2005-04       Impact factor: 2.689

4.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

5.  Continuation of initial antihypertensive medication after 1 year of therapy.

Authors:  B S Bloom
Journal:  Clin Ther       Date:  1998 Jul-Aug       Impact factor: 3.393

6.  A comparison of outcomes with angiotensin-converting--enzyme inhibitors and diuretics for hypertension in the elderly.

Authors:  Lindon M H Wing; Christopher M Reid; Philip Ryan; Lawrence J Beilin; Mark A Brown; Garry L R Jennings; Colin I Johnston; John J McNeil; Graham J Macdonald; John E Marley; Trefor O Morgan; Malcolm J West
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

7.  Antihypertensive persistence and drug class.

Authors:  Michael A Marentette; William C Gerth; David K Billings; Kelly B Zarnke
Journal:  Can J Cardiol       Date:  2002-06       Impact factor: 5.223

8.  Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension.

Authors:  A I Goldberg; M C Dunlay; C S Sweet
Journal:  Am J Cardiol       Date:  1995-04-15       Impact factor: 2.778

9.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

10.  Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

Authors:  Lars H Lindholm; Mats Persson; Petar Alaupovic; Bo Carlberg; Anders Svensson; Ola Samuelsson
Journal:  J Hypertens       Date:  2003-08       Impact factor: 4.844

View more
  3 in total

Review 1.  Treatment of isolated systolic hypertension.

Authors:  Gordon S Stokes
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

2.  Screening, treatment, and control of hypertension in US private physician offices, 2003-2004.

Authors:  Jun Ma; Randall S Stafford
Journal:  Hypertension       Date:  2008-03-17       Impact factor: 10.190

3.  Changing patterns of initial drug therapy for the treatment of hypertension in a Medicaid population, 2001-2005.

Authors:  Robert Weiss; Kevin Buckley; Timothy Clifford
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-10       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.